Short Interest in CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Expands By 13.1%

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) was the recipient of a significant increase in short interest in the month of April. As of April 15th, there was short interest totaling 468,369 shares, an increase of 13.1% from the March 31st total of 414,235 shares. Based on an average daily trading volume, of 72,037 shares, the days-to-cover ratio is presently 6.5 days. Approximately 1.4% of the company’s shares are short sold.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Rodman & Renshaw began coverage on shares of CAMP4 Therapeutics in a research note on Tuesday, April 14th. They issued a “buy” rating and a $7.00 price objective for the company. Leerink Partners upped their price objective on shares of CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of CAMP4 Therapeutics in a research report on Friday, March 6th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $8.60.

Institutional Trading of CAMP4 Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CAMP. Bridgeway Capital Management LLC purchased a new position in shares of CAMP4 Therapeutics during the second quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. bought a new position in CAMP4 Therapeutics during the 4th quarter valued at $61,000. Jefferies Financial Group Inc. bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth $70,000. Bank of America Corp DE purchased a new stake in shares of CAMP4 Therapeutics in the fourth quarter valued at about $86,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at about $115,000.

CAMP4 Therapeutics Trading Down 2.9%

NASDAQ CAMP traded down $0.12 during mid-day trading on Friday, hitting $4.05. The company’s stock had a trading volume of 104,294 shares, compared to its average volume of 72,033. The firm has a market capitalization of $210.32 million, a price-to-earnings ratio of -1.52 and a beta of 0.04. The company’s 50 day simple moving average is $4.66 and its 200 day simple moving average is $4.58. CAMP4 Therapeutics has a twelve month low of $1.30 and a twelve month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last released its quarterly earnings data on Thursday, March 5th. The Wireless communications provider reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.56). The business had revenue of $0.35 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,298.54% and a negative return on equity of 162.49%. As a group, research analysts forecast that CAMP4 Therapeutics will post -0.78 EPS for the current year.

CAMP4 Therapeutics Company Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.